about
Relationship and interactions of curcumin with radiation therapyChromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomasThe Role of Poly(ADP-ribose) Polymerase-1 in Rheumatoid ArthritisChemical Disruption of Wnt-dependent Cell Fate Decision-making Mechanisms in Cancer and Regenerative MedicineNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewPARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directionsPARP-1 expression is increased in colon adenoma and carcinoma and correlates with OGG1Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer.Two decades after BRCA: setting paradigms in personalized cancer care and preventionDifferential promoter methylation of kinesin family member 1a in plasma is associated with breast cancer and DNA repair capacityNAD+ and sirtuins in aging and disease.Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogenePARP-1 inhibition influences the oxidative stress response of the human lens.PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiencyGenomic Biomarkers for Breast Cancer Risk.PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.Embracing synthetic lethality of novel anticancer therapies.Design, Synthesis, and Biological Evaluation of Novel PARP-1 Inhibitors Based on a 1H-Thieno[3,4-d] Imidazole-4-Carboxamide Scaffold.Oxidatively-generated damage to DNA and proteins mediated by photosensitized UVALoss of ubiquitin E2 Ube2w rescues hypersensitivity of Rnf4 mutant cells to DNA damageCancer-Targeted Selenium Nanoparticles Sensitize Cancer Cells to Continuous γ Radiation to Achieve Synergetic Chemo-Radiotherapy.Whole proteome analysis of human tankyrase knockout cells reveals targets of tankyrase-mediated degradation.PARP1 changes from three-dimensional DNA damage searching to one-dimensional diffusion after auto-PARylation or in the presence of APE1.Prediction of PARP Inhibition with Proteochemometric Modelling and Conformal Prediction.
P2860
Q26746150-321FE72B-1136-449B-B0C7-06E11072DB67Q26751724-47230F36-7CA2-450E-8E12-64E75CACA3EDQ26785513-723906BB-DA37-4307-A2E7-9E241326D559Q26796673-2FA45A6D-BB40-41F7-84E2-615FA4DB4F9FQ27304386-9B487895-D795-4A96-9E82-A29F67DDEE84Q28071345-FEB3FB9E-5904-4DA1-8C97-ED3457DD4BF6Q28254261-4E390F88-9BF2-4688-854E-0677C0CA23B1Q33598001-AD36D40F-68EF-455C-A924-D85F42611D33Q33820594-1840D2AA-730D-427C-9EB0-B329CFDFC716Q33881701-260B4265-14A4-4EB7-AEA3-D4CCEEA9603FQ33955066-07562B49-1979-4889-A0B0-74018BEDD1E7Q36413813-0DF1ABF3-F29D-4EAA-8167-ADD55DBBEF6DQ36703885-03E7021F-CD22-400F-A84E-9E2FA836D8E9Q37057758-4A8C500C-06E0-440B-879F-C86E8390824FQ37242239-327A5E75-862A-45DA-8E62-06FAFD986EC5Q37607283-D8735136-B823-4224-8BF2-39373665B8B6Q38554530-61EF3C5E-30D4-43ED-9BCD-26B4B09F2CBEQ38764341-CCCC9784-3AE3-44FF-87FA-958BAEA291FCQ39042732-5CAE99C1-6593-4C4D-99D4-A83C6D3CA7D6Q39761629-A58EB92B-30BC-4860-8007-D88B300E351CQ46309055-24A98C3D-B166-4B8E-9548-26E338155042Q47103031-55E9052A-2692-469A-A5EA-AF520DA7B08FQ47114253-33EDA9E9-7009-4100-AC93-26EE73F8003AQ51595152-600B3BD5-1C99-41F0-8A16-038B78E568AA
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
PARP inhibitors for anticancer therapy.
@en
type
label
PARP inhibitors for anticancer therapy.
@en
prefLabel
PARP inhibitors for anticancer therapy.
@en
P2860
P356
P1476
PARP inhibitors for anticancer therapy.
@en
P2093
Nicola Curtin
P2860
P356
10.1042/BST20130187
P577
2014-02-01T00:00:00Z